SpaceOAR® hydrogel is an option for men who undergo radiation treatment for prostate cancer. It acts as a spacer providing space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment. Patients may be awake or asleep under general anesthesia for the procedure. SpaceOAR® hydrogel is not painful, remains stable during radiation therapy and then is gradually absorbed by the body after radiation therapy has been completed.
SpaceOAR® Hydrogel reduces rectal injury in men receiving prostate cancer radiation therapy (RT) by acting as a spacer – pushing the rectum away from the prostate.
Proven Clinical Results
Results from a randomized clinical trial demonstrated that 3 years following radiation treatment, patients who received SpaceOAR® hydrogel prior to their radiation treatment were:
- Bowel: 66% fewer SpaceOAR® hydrogel patients experienced clinically significant declines in detectable bowel quality of life (1X the Minimal Important Difference)1
- Urinary: 65% fewer SpaceOAR® hydrogel patients experienced clinically significant declines (2X the Minimal Important Difference) in detectable urinary quality of life1
- Sexual: SpaceOAR® hydrogel patients who had erections sufficient for intercourse at baseline were 78% more likely to retain sexual function at 3 years2
- SpaceOAR® hydrogel is cleared by the FDA and more than 15,000 patients worldwide have been successfully treated.
- SpaceOAR® is a registered trademark of Augmenix Inc.
For more information, please download the patient brochure.
- Hamstra D, et al. Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys; Dec. 2016 DOI
- Hamstra D, et al. Evaluation of sexual function on a randomized trial of a prostate rectal spacer. J Clin Oncol 35, 2017 (suppl 6S; abstract 69)